BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 35203244)

  • 1. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
    Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of CTCL cell lines reveals important differences between mycosis fungoides/Sézary syndrome
    Netchiporouk E; Gantchev J; Tsang M; Thibault P; Watters AK; Hughes JM; Ghazawi FM; Woetmann A; Ødum N; Sasseville D; Litvinov IV
    Oncotarget; 2017 Nov; 8(56):95981-95998. PubMed ID: 29221181
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary cutaneous CD30(+) lymphoproliferative disorders.
    Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
    J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30-Positive Lymphoproliferative Disorders.
    Nikolaenko L; Zain J; Rosen ST; Querfeld C
    Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
    DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
    Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL).
    Bunn PA; Foss FM
    J Cell Biochem Suppl; 1996; 24():12-23. PubMed ID: 8806090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-3 Expression in Primary Cutaneous CD30-Positive Lymphoproliferative Disorders and Transformed Mycosis Fungoides.
    Mitteldorf C; Robson A; Tronnier M; Pfaltz MC; Kempf W
    Dermatology; 2015; 231(2):164-70. PubMed ID: 26111483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.
    Fouchard N; Mahe A; Huerre M; Fraitag S; Valensi F; Macintyre E; Sanou F; de The G; Gessain A
    Leukemia; 1998 Apr; 12(4):578-85. PubMed ID: 9557617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
    Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
    Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
    Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
    Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
    Nguyen GH; Olson LC; Magro CM
    Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOX expression in different subtypes of cutaneous lymphoma.
    Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
    Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature.
    Stowman AM; Hsia LL; Kanner WA; Mahadevan MS; Bullock GC; Patterson JW
    Int J Dermatol; 2016 Feb; 55(2):e62-71. PubMed ID: 26266670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?
    Cieza-Díaz DE; Prieto-Torres L; Rodríguez-Pinilla SM; Córdoba Mascuñano R; Manso Alonso R; Machan S; Piris Pinilla MÁ; Requena Caballero L
    Am J Dermatopathol; 2019 Nov; 41(11):846-850. PubMed ID: 30946099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SATB1 Defines a Subtype of Cutaneous CD30
    Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
    J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary cutaneous lymphoma-a case series of 163 patients].
    Nashan D; Friedrich CM; Geissler E; Schmitt-Graeff A; Klein F; Meiss F
    Hautarzt; 2018 Dec; 69(12):1014-1020. PubMed ID: 29881891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
    Mehdi SJ; Moerman-Herzog A; Wong HK
    BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
    J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.